Nurix Therapeutics, Inc. NRIX
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is an oncology drug developer. Its lead program, bexobrutideg (NX-5948), is in Phase 3 for Relapsed/refractory CLL.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| bexobrutideg | CLL (DAYBreak CLL-306) | small molecule | Phase 3 |
Recent results and decisions
- Jun 8, 2026n/a Nurix-Roche global collaboration on bexobrutideg: $700M upfront, up to $2.3B total, 40/60 global development cost split, 50/50 US profit share, low-to-high-teens ex-US royalties; closing subject to HSR clearance.
Co-development and co-commercialization in the U.S. accelerates Nurix’s evolution into a fully integrated biopharmaceutical company in major medical markets
Filing - Jan 12, 2026positive Recap of ASH 2025 data: 83% ORR (2 CRs) in CLL patients with median 4 prior lines, median PFS 22.1 months, no dose-limiting toxicities.
Highlights included an 83% objective response rate, including two complete responses (4.3%) in CLL patients with a median of four prior lines of treatment.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.